EA200300663A1 - Антагонисты cxcr3 - Google Patents
Антагонисты cxcr3Info
- Publication number
- EA200300663A1 EA200300663A1 EA200300663A EA200300663A EA200300663A1 EA 200300663 A1 EA200300663 A1 EA 200300663A1 EA 200300663 A EA200300663 A EA 200300663A EA 200300663 A EA200300663 A EA 200300663A EA 200300663 A1 EA200300663 A1 EA 200300663A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- inflammatory
- diseases
- applicable
- treatment
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
Abstract
Предложены соединения, композиции и способы, которые применимы при лечении воспалительных и иммунных состояний и заболеваний. В частности, изобретение относится к соединениям, которые модулируют экспрессию и/или функцию рецептора хемокина. Предложенные способы применимы для лечения воспалительных и иммунорегуляторных расстройств и заболеваний, таких как рассеянный склероз, ревматоидный артрит и диабет типа I.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25524100P | 2000-12-11 | 2000-12-11 | |
US29649901P | 2001-06-06 | 2001-06-06 | |
PCT/US2001/047850 WO2002083143A1 (en) | 2000-12-11 | 2001-12-11 | Cxcr3 antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200300663A1 true EA200300663A1 (ru) | 2004-06-24 |
EA007538B1 EA007538B1 (ru) | 2006-10-27 |
Family
ID=26944548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200300663A EA007538B1 (ru) | 2000-12-11 | 2001-12-11 | Антагонисты cxcr3 |
Country Status (19)
Country | Link |
---|---|
US (3) | US6964967B2 (ru) |
EP (1) | EP1343505A1 (ru) |
JP (1) | JP4259877B2 (ru) |
KR (1) | KR100883184B1 (ru) |
CN (1) | CN1575177A (ru) |
AU (1) | AU2001297717B2 (ru) |
BR (1) | BR0116096A (ru) |
CA (1) | CA2431553A1 (ru) |
CZ (1) | CZ20031910A3 (ru) |
EA (1) | EA007538B1 (ru) |
HU (1) | HUP0500880A2 (ru) |
IL (2) | IL156304A0 (ru) |
MX (1) | MXPA03005152A (ru) |
NO (1) | NO325450B1 (ru) |
NZ (1) | NZ526622A (ru) |
PL (1) | PL366311A1 (ru) |
SK (1) | SK8752003A3 (ru) |
WO (1) | WO2002083143A1 (ru) |
ZA (1) | ZA200304342B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2617989C2 (ru) * | 2006-09-26 | 2017-05-02 | Селджин Корпорейшн | Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения |
Families Citing this family (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1163237B1 (en) | 1999-03-17 | 2004-05-06 | AstraZeneca AB | Amide derivatives |
US7230000B1 (en) | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
US7671200B2 (en) | 1999-10-27 | 2010-03-02 | Cytokinetics, Inc. | Quinazolinone KSP inhibitors |
US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
EP1343505A1 (en) * | 2000-12-11 | 2003-09-17 | Tularik Inc. | Cxcr3 antagonists |
US6794379B2 (en) * | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
MXPA04006136A (es) | 2001-12-21 | 2004-11-01 | Anormed Inc | Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada. |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
US7354932B2 (en) * | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
EP1465869B1 (en) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulators of lxr |
US7009049B2 (en) | 2002-02-15 | 2006-03-07 | Cytokinetics, Inc. | Syntheses of quinazolinones |
WO2003076418A1 (en) * | 2002-03-07 | 2003-09-18 | X-Ceptor Therapeutics, Inc. | Quinazolinone modulators of nuclear receptors |
US6900219B2 (en) | 2002-04-04 | 2005-05-31 | Cv Therapeutics, Inc. | ABCA-1 elevating compounds |
PL211300B1 (pl) | 2002-04-17 | 2012-05-31 | Cytokinetics Inc | Związek i kompozycja zawierająca ten związek |
US7166595B2 (en) * | 2002-05-09 | 2007-01-23 | Cytokinetics, Inc. | Compounds, methods and compositions |
EP1553931A4 (en) * | 2002-05-09 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
US7244555B2 (en) * | 2002-05-14 | 2007-07-17 | Renovak Inc | Systems and methods for identifying organ transplant risk |
AU2003299517A1 (en) * | 2002-05-23 | 2004-05-25 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
AU2003265242A1 (en) | 2002-05-23 | 2003-12-22 | Cytokinetics, Inc. | Compounds, compositions, and methods |
EP1556357A4 (en) * | 2002-06-14 | 2006-09-13 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
DE60326248D1 (de) | 2002-07-17 | 2009-04-02 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen |
US7211580B2 (en) | 2002-07-23 | 2007-05-01 | Cytokinetics, Incorporated | Compounds, compositions, and methods |
EP1539180A4 (en) * | 2002-08-21 | 2006-08-30 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
WO2004024086A2 (en) * | 2002-09-13 | 2004-03-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
US7557115B2 (en) | 2002-09-30 | 2009-07-07 | Cytokinetics, Inc. | Compounds, compositions, and methods |
DE10301650A1 (de) * | 2003-01-17 | 2004-07-29 | Johannes-Gutenberg-Universität Mainz | Medizinisch nützliche 1-Phenyl-2-aminomethylnaphthaline, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und deren Verwendung |
US7358262B2 (en) | 2003-01-29 | 2008-04-15 | Whitehead Institute For Biomedical Research | Identification of genotype-selective anti-tumor agents |
US20040242498A1 (en) * | 2003-02-27 | 2004-12-02 | Collins Tassie L. | CXCR3 antagonists |
SE0300627D0 (sv) * | 2003-03-07 | 2003-03-07 | Astrazeneca Ab | Novel fused heterocycles and uses therof |
WO2004078758A1 (en) * | 2003-03-07 | 2004-09-16 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
CN1894234A (zh) | 2003-03-25 | 2007-01-10 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
US7399776B2 (en) | 2003-04-02 | 2008-07-15 | Taigen Biotechnology | Polyamine compounds for treating chemokine receptor mediated diseases |
US7504422B2 (en) | 2003-04-02 | 2009-03-17 | Taigen Biotechnology Co. Ltd. | Polyamine compounds |
US7378524B2 (en) | 2003-04-11 | 2008-05-27 | Taigen Biotechnology Co., Ltd. | Aminoquinoline compounds |
JP2006522814A (ja) * | 2003-04-11 | 2006-10-05 | タイゲン・バイオテクノロジー | アミノキノリン化合物 |
US7741341B2 (en) * | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
US7345046B2 (en) | 2003-05-30 | 2008-03-18 | Chiron Corporation | Heteroaryl-fused pyrimidinyl compounds as anticancer agents |
AU2004249730A1 (en) | 2003-06-20 | 2004-12-29 | Novartis Vaccines And Diagnostics, Inc. | Pyridino(1,2-A)pyrimidin-4-one compounds as anticancer agents |
AU2004253473B2 (en) * | 2003-06-24 | 2010-03-04 | University Of Connecticut | Methods of inhibiting vascular permeability and apoptosis |
MXPA06001601A (es) | 2003-08-13 | 2006-08-25 | Takeda Pharmaceutical | Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa. |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7442709B2 (en) | 2003-08-21 | 2008-10-28 | Osi Pharmaceuticals, Inc. | N3-substituted imidazopyridine c-Kit inhibitors |
AU2004268948A1 (en) | 2003-08-21 | 2005-03-10 | Osi Pharmaceuticals, Inc. | N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors |
JP2006193426A (ja) * | 2003-09-05 | 2006-07-27 | Sankyo Co Ltd | 置換された縮環ピリミジン−4(3h)−オン化合物 |
WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
EP1670456A2 (en) * | 2003-10-06 | 2006-06-21 | Cytokinetics, Inc. | Compounds, compositions and methods |
GB0324790D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
WO2005041888A2 (en) * | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
EP1680420A4 (en) * | 2003-11-07 | 2008-09-24 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
EP1692112A4 (en) | 2003-12-08 | 2008-09-24 | Cytokinetics Inc | COMPOUNDS, COMPOSITIONS, AND METHODS |
SE0303491D0 (sv) * | 2003-12-19 | 2003-12-19 | Astrazeneca Ab | New use VI |
WO2005087229A1 (en) * | 2004-03-08 | 2005-09-22 | Wyeth | Ion channel modulators |
CA2558813A1 (en) * | 2004-03-09 | 2005-09-15 | Kyoto University | Pharmaceutical composition comprising cxcr3 inhibitor |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN102079743B (zh) | 2004-03-15 | 2020-08-25 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
RU2385867C2 (ru) | 2004-05-21 | 2010-04-10 | Новартис Аг | Замещенные производные хинолина как ингибиторы митотического кинезина |
WO2005118555A1 (en) | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
US7375102B2 (en) * | 2004-06-28 | 2008-05-20 | Amgen Sf, Llc | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use |
US7939538B2 (en) * | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
US7271271B2 (en) * | 2004-06-28 | 2007-09-18 | Amgen Sf, Llc | Imidazolo-related compounds, compositions and methods for their use |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
UY29070A1 (es) | 2004-08-18 | 2006-03-31 | Astrazeneca Ab | Enantiómeros de heterocíclicos fusionados y sus usos |
WO2006026597A2 (en) * | 2004-08-30 | 2006-03-09 | Smithkline Beecham Corporation | Novel compositions and methods of treatment |
PE20060598A1 (es) | 2004-09-13 | 2006-08-21 | Ono Pharmaceutical Co | Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5 |
JP4698991B2 (ja) * | 2004-09-14 | 2011-06-08 | 日本曹達株式会社 | ピリジルメチルカルバミン酸エステル化合物、その製造方法及びピリジルメチルアミン化合物の製造方法 |
CA2584412C (en) * | 2004-09-14 | 2017-05-09 | Minerva Biotechnologies Corporation | Methods for diagnosis and treatment of cancer |
JP2008520744A (ja) | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 抗炎症性ピラゾロピリミジン |
AU2005312028A1 (en) | 2004-12-01 | 2006-06-08 | Osi Pharmaceuticals, Inc. | N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
US7501526B2 (en) | 2005-01-20 | 2009-03-10 | Taigen Biotechnology | Synthesis of polyamine compounds |
EP1848698B1 (en) * | 2005-01-25 | 2013-03-13 | Prolexys Pharmaceuticals, Inc. | Quinoxaline derivatives as antitumor agents |
ATE518855T1 (de) * | 2005-02-16 | 2011-08-15 | Schering Corp | Neue heterozyklische substituierte pyridin- oder phenylverbindungen mit cxcr3-antagonistischer aktivität |
JP2008530213A (ja) * | 2005-02-16 | 2008-08-07 | シェーリング コーポレイション | Cxcr3アンタゴニスト活性を有する、ヘテロアリールで置換されたピラジニル−ピペラジン−ピペリジン |
US7868005B2 (en) * | 2005-02-16 | 2011-01-11 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity |
TW200714610A (en) * | 2005-02-16 | 2007-04-16 | Univ Maryland | CXCR3 is a gliadin receptor |
CN101163692B (zh) * | 2005-02-16 | 2012-01-18 | 先灵公司 | 具有cxcr3拮抗活性的杂环取代的哌嗪 |
EP1856097B1 (en) * | 2005-02-16 | 2012-07-11 | Schering Corporation | Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
CN101189238A (zh) * | 2005-02-16 | 2008-05-28 | 先灵公司 | 具有cxcr3拮抗剂活性的哌嗪-哌啶 |
EP1889622A4 (en) | 2005-05-31 | 2009-12-23 | Ono Pharmaceutical Co | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF |
EP1917250B1 (en) | 2005-06-27 | 2010-07-21 | Amgen, Inc | Anti-inflammatory aryl nitrile compounds |
US20080312215A1 (en) * | 2005-06-28 | 2008-12-18 | Pharmacopeia Drug Discovery, Inc. | Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders |
US7790679B2 (en) * | 2005-08-05 | 2010-09-07 | Amgen Inc. | Pharmaceutical formulations |
PE20070622A1 (es) * | 2005-09-14 | 2007-08-22 | Takeda Pharmaceutical | Administracion de inhibidores de dipeptidil peptidasa |
WO2007033350A1 (en) | 2005-09-14 | 2007-03-22 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors for treating diabetes |
EP1924567B1 (en) | 2005-09-16 | 2012-08-22 | Takeda Pharmaceutical Company Limited | Process for the preparation of pyrimidinedione derivatives |
US8575143B2 (en) * | 2005-12-22 | 2013-11-05 | Prolexys Pharmaceuticals, Inc. | 3-aryl-substituted quinazolones, and uses thereof |
EP1995246A4 (en) | 2006-03-10 | 2010-11-17 | Ono Pharmaceutical Co | NITROGENATED HETEROCYCLIC DERIVATIVE AND MEDICAMENT WITH DERIVATIVE ACTIVE SUBSTANCE |
CA2646958A1 (en) * | 2006-03-21 | 2007-09-27 | Schering Corporation | Heterocyclic substituted pyridine compounds with cxcr3 antagonist activity |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CA2647391C (en) | 2006-04-04 | 2015-12-29 | The Regents Of The University Of California | Kinase antagonists |
AR061975A1 (es) * | 2006-07-14 | 2008-08-10 | Schering Corp | Compuestos de piperazina 1,4-sustituida con actividad antagonista de cxcr3, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de quimioquina cxcr3 |
US20090325992A1 (en) | 2006-07-31 | 2009-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
US7820689B2 (en) * | 2006-08-10 | 2010-10-26 | Hua-Lin Wu | Methods and compositions for preventing or treating cardiovascular disease |
CA2663279C (en) * | 2006-09-13 | 2016-05-17 | Takeda Pharmaceutical Company Limited | Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
EP2079739A2 (en) | 2006-10-04 | 2009-07-22 | Pfizer Products Inc. | Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists |
CN101605797A (zh) * | 2006-11-13 | 2009-12-16 | 伊莱利利公司 | 治疗炎症疾病和癌症的噻吩并嘧啶酮 |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
CN101622247A (zh) | 2007-01-05 | 2010-01-06 | 诺瓦提斯公司 | 作为驱动蛋白纺锤体蛋白抑制剂的咪唑衍生物 |
CN101796073B (zh) * | 2007-02-01 | 2014-08-13 | 特瓦生物制药美国有限公司 | 针对cxcr3的人源化抗体 |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
CN101678082B (zh) | 2007-03-26 | 2013-06-19 | 再生医药有限公司 | 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法 |
EP2185154A2 (en) * | 2007-08-03 | 2010-05-19 | Schering Corporation | Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines |
WO2009046448A1 (en) | 2007-10-04 | 2009-04-09 | Intellikine, Inc. | Chemical entities and therapeutic uses thereof |
SG185996A1 (en) * | 2007-11-13 | 2012-12-28 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8703777B2 (en) | 2008-01-04 | 2014-04-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
WO2009094168A1 (en) * | 2008-01-22 | 2009-07-30 | Amgen Inc. | Cxcr3 antagonists |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
WO2010006072A2 (en) | 2008-07-08 | 2010-01-14 | The Regents Of The University Of California | Mtor modulators and uses thereof |
WO2010006086A2 (en) | 2008-07-08 | 2010-01-14 | Intellikine, Inc. | Kinase inhibitors and methods of use |
CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
EP2358720B1 (en) | 2008-10-16 | 2016-03-02 | The Regents of The University of California | Fused ring heteroaryl kinase inhibitors |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン, エルエルシー | 複素環式化合物およびその使用 |
WO2011032277A1 (en) * | 2009-09-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | Quinazolinone derivatives as viral polymerase inhibitors |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
JP5951600B2 (ja) | 2010-05-21 | 2016-07-13 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | キナーゼ調節のための、化合物、組成物および方法 |
CA2817577A1 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
TWI592411B (zh) | 2011-02-23 | 2017-07-21 | 英特爾立秦有限責任公司 | 激酶抑制劑之組合及其用途 |
EP2524912A1 (en) | 2011-05-16 | 2012-11-21 | Bionomics Limited | Amine derivatives |
AU2012255690B2 (en) | 2011-05-16 | 2015-06-11 | Bionomics Limited | Amine derivatives as potassium channel blockers |
WO2013041833A1 (en) * | 2011-06-13 | 2013-03-28 | Ith Immune Therapy Holdings Ab | Treating conditions associated with metabolic syndrome |
AU2012284088B2 (en) | 2011-07-19 | 2015-10-08 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
EP2751093A1 (en) | 2011-08-29 | 2014-07-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP6342805B2 (ja) | 2011-09-02 | 2018-06-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 置換ピラゾロ[3,4−d]ピリミジンおよびその用途 |
WO2013060865A1 (en) | 2011-10-28 | 2013-05-02 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP2855508B1 (en) | 2012-06-01 | 2018-02-14 | Allergan, Inc. | Cyclosporin a analogs |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
BR112015006828A8 (pt) | 2012-09-26 | 2019-09-17 | Univ California | composto, ou um sal farmaceuticamente aceitável do mesmo; composição farmacêutica; uso do composto; e método para modular a atividade de uma proteína ire1 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PE20160685A1 (es) | 2013-10-04 | 2016-07-23 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos y usos de los mismos |
SG10201808053XA (en) | 2014-03-19 | 2018-10-30 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
TW201639873A (zh) | 2015-01-08 | 2016-11-16 | 歐樂根公司 | Mebmt側鏈已環化之環孢菌素衍生物 |
US10118900B2 (en) | 2015-08-25 | 2018-11-06 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as CB-1 inverse agonists |
WO2017048702A1 (en) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
EP3389634B1 (en) | 2015-12-14 | 2021-10-06 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
CN109069486A (zh) | 2015-12-14 | 2018-12-21 | X4 制药有限公司 | 治疗癌症的方法 |
SI3393468T1 (sl) | 2015-12-22 | 2023-01-31 | X4 Pharmaceuticals, Inc. | Postopki za zdravljenje bolezni imunske pomanjkljivosti |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス4 ファーマシューティカルズ, インコーポレイテッド | 癌を処置する方法 |
WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2017223243A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
EP3471726A4 (en) | 2016-06-21 | 2019-10-09 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
US10759796B2 (en) | 2016-06-21 | 2020-09-01 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
CN109640999A (zh) | 2016-06-24 | 2019-04-16 | 无限药品股份有限公司 | 组合疗法 |
US20180164221A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
CN108794496B (zh) * | 2018-04-28 | 2020-04-24 | 北京施安泰医药技术开发有限公司 | 一类cdk抑制剂、其药物组合物、制备方法及用途 |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
KR20240005019A (ko) | 2021-05-06 | 2024-01-11 | 바이엘 악티엔게젤샤프트 | 알킬아미드 치환된, 환형 이미다졸 및 살충제로서의 이의 용도 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2665159B1 (fr) | 1990-07-24 | 1992-11-13 | Rhone Poulenc Sante | Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent. |
EP0481614A1 (en) | 1990-10-01 | 1992-04-22 | Merck & Co. Inc. | Substituted pyridopyrimidinones and related heterocycles as angiotensin II antagonists |
US5202322A (en) | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
US5256667A (en) | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
US5756502A (en) | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
US5719144A (en) | 1995-02-22 | 1998-02-17 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
WO1996028444A1 (en) | 1995-03-15 | 1996-09-19 | Pfizer Inc. | 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS |
MX9800921A (es) | 1995-08-02 | 1998-05-31 | Chirotech Technology Ltd | Quinolonas y su uso terapeutico. |
US6140064A (en) | 1996-09-10 | 2000-10-31 | Theodor-Kocher Institute | Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3 |
NZ334125A (en) | 1996-09-25 | 2000-10-27 | Zeneca Ltd | Quinoline derivatives inhibiting the effect of growth factors such as VEGF |
AU5380398A (en) | 1996-12-17 | 1998-07-15 | E.I. Du Pont De Nemours And Company | Fungicidal quinazolinones |
FR2778662B1 (fr) | 1998-05-12 | 2000-06-16 | Adir | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DE60031285T2 (de) * | 1999-08-27 | 2007-08-30 | Chemocentryx Inc., Mountain View | Heterozyclische verbindungen und verfahren zur modulierung von cxcr3 funktion |
EP1216234B1 (en) * | 1999-09-16 | 2004-12-29 | Curis, Inc. | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
DE60028227T2 (de) * | 1999-10-27 | 2007-03-29 | Cytokinetics, Inc., South San Francisco | Chinazolinone benutzende verfahren und zusammenstellungen |
US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
DE50112961D1 (de) | 2000-02-01 | 2007-10-18 | Abbott Gmbh & Co Kg | Heterozyklische verbindungen und deren anwendung als parp-inhibitoren |
GB2359551A (en) * | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
GB2361003A (en) * | 2000-04-07 | 2001-10-10 | Astrazeneca Ab | Novel compounds |
AU2002211828A1 (en) | 2000-10-02 | 2002-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
EP1343505A1 (en) | 2000-12-11 | 2003-09-17 | Tularik Inc. | Cxcr3 antagonists |
US6794379B2 (en) * | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
AU2004249730A1 (en) * | 2003-06-20 | 2004-12-29 | Novartis Vaccines And Diagnostics, Inc. | Pyridino(1,2-A)pyrimidin-4-one compounds as anticancer agents |
-
2001
- 2001-12-11 EP EP01273533A patent/EP1343505A1/en not_active Withdrawn
- 2001-12-11 KR KR1020037007789A patent/KR100883184B1/ko not_active IP Right Cessation
- 2001-12-11 CA CA002431553A patent/CA2431553A1/en not_active Abandoned
- 2001-12-11 JP JP2002580947A patent/JP4259877B2/ja not_active Expired - Fee Related
- 2001-12-11 NZ NZ526622A patent/NZ526622A/en unknown
- 2001-12-11 US US10/015,532 patent/US6964967B2/en not_active Expired - Lifetime
- 2001-12-11 PL PL01366311A patent/PL366311A1/xx not_active Application Discontinuation
- 2001-12-11 MX MXPA03005152A patent/MXPA03005152A/es active IP Right Grant
- 2001-12-11 SK SK875-2003A patent/SK8752003A3/sk unknown
- 2001-12-11 AU AU2001297717A patent/AU2001297717B2/en not_active Ceased
- 2001-12-11 EA EA200300663A patent/EA007538B1/ru not_active IP Right Cessation
- 2001-12-11 BR BR0116096-6A patent/BR0116096A/pt not_active Application Discontinuation
- 2001-12-11 WO PCT/US2001/047850 patent/WO2002083143A1/en active IP Right Grant
- 2001-12-11 IL IL15630401A patent/IL156304A0/xx active IP Right Grant
- 2001-12-11 CN CNA018225969A patent/CN1575177A/zh active Pending
- 2001-12-11 CZ CZ20031910A patent/CZ20031910A3/cs unknown
- 2001-12-11 HU HU0500880A patent/HUP0500880A2/hu unknown
-
2002
- 2002-08-29 US US10/231,895 patent/US7053215B2/en not_active Expired - Lifetime
-
2003
- 2003-06-03 ZA ZA2003/04342A patent/ZA200304342B/en unknown
- 2003-06-04 IL IL156304A patent/IL156304A/en not_active IP Right Cessation
- 2003-06-10 NO NO20032612A patent/NO325450B1/no not_active IP Right Cessation
-
2006
- 2006-01-13 US US11/332,054 patent/US20060116388A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2617989C2 (ru) * | 2006-09-26 | 2017-05-02 | Селджин Корпорейшн | Производные 5-замещенного хиназолинона, содержащие их композиции и способы их применения |
Also Published As
Publication number | Publication date |
---|---|
NO20032612D0 (no) | 2003-06-10 |
CN1575177A (zh) | 2005-02-02 |
HUP0500880A2 (en) | 2006-05-29 |
EA007538B1 (ru) | 2006-10-27 |
NO325450B1 (no) | 2008-05-05 |
AU2001297717B2 (en) | 2006-02-23 |
MXPA03005152A (es) | 2004-10-14 |
IL156304A0 (en) | 2004-01-04 |
NO20032612L (no) | 2003-08-05 |
ZA200304342B (en) | 2005-08-31 |
US20020169159A1 (en) | 2002-11-14 |
SK8752003A3 (en) | 2003-11-04 |
JP4259877B2 (ja) | 2009-04-30 |
NZ526622A (en) | 2006-07-28 |
KR20030080212A (ko) | 2003-10-11 |
CZ20031910A3 (cs) | 2003-12-17 |
US6964967B2 (en) | 2005-11-15 |
JP2004536796A (ja) | 2004-12-09 |
CA2431553A1 (en) | 2002-10-24 |
EP1343505A1 (en) | 2003-09-17 |
IL156304A (en) | 2009-02-11 |
US20060116388A1 (en) | 2006-06-01 |
PL366311A1 (en) | 2005-01-24 |
KR100883184B1 (ko) | 2009-02-12 |
US20030055054A1 (en) | 2003-03-20 |
BR0116096A (pt) | 2005-10-18 |
WO2002083143A1 (en) | 2002-10-24 |
US7053215B2 (en) | 2006-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200300663A1 (ru) | Антагонисты cxcr3 | |
EA200700169A1 (ru) | Конденсированные производные пиримидина и их композиции, применимые в качестве модуляторов cxcr3 рецепторов для профилактики и лечения воспалительных и иммунорегуляторных расстройств и заболеваний | |
EP1017713A4 (en) | CYCLIC AGONISTS AND ANTAGONISTS OF THE C5A RECEPTORS AND G-PROTEIN COUPLED RECEPTORS | |
EA200100103A1 (ru) | Ингибиторы адгезии клеток | |
FI963101A0 (fi) | Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut | |
BRPI0314814C1 (pt) | anticorpo compreendendo uma variante de fc | |
NO974258D0 (no) | IL-17-reseptor | |
RS52769B (sr) | Kompozicije i postupci za povećanje mineralizacije kostiju | |
EA200300441A1 (ru) | Ассоциация антагониста рецептора св1 и сибутрамина, содержащие их фармацевтические композиции и их применение для лечения ожирения | |
ES2190503T3 (es) | Heterociclos de 5 anillos en calidad de inhibidores de la adhesion de leucocitos y antagonistas de vla-4. | |
MY123865A (en) | Novel heterocycles as inhibitors of leucocyte adhesion and as vla-4 antagonists | |
BR0313059B8 (pt) | composto, e, composição farmacêutica | |
ME00804B (me) | Anti-alpha v beta 6 antitela | |
EA200001176A1 (ru) | Гетероциклические ингибиторы p38 | |
PE20001316A1 (es) | Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene | |
TR200102733T2 (tr) | IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri | |
EA200001041A1 (ru) | Антитела к cd23, их производные и их терапевтическое применение | |
BR9907743A (pt) | Anticorpos contra a il-12 humana | |
ATE439166T1 (de) | Hemmung von il-17 produktion | |
IL171356A (en) | Anti-interferon receptor antibody for treatment of inflammatory bowel disease | |
MY193349A (en) | Anti-vegf protein compositions and methods for producing the same | |
WO2003073982A3 (en) | Anti-interleukin-1 beta analogs | |
MXPA03007413A (es) | Composicion y metodo para tratar enfermedades inflamatorias. | |
ATE402958T1 (de) | Antagonisten des ige-rezeptors | |
DK1567018T3 (da) | Fremgangsmåde til at forbedre immunfunktionen hos pattedyr ved anvendelse af lactobacillus reuteri stammer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
PC4A | Registration of transfer of a eurasian patent by assignment | ||
PD4A | Registration of transfer of a eurasian patent in accordance with the succession in title | ||
TC4A | Change in name of a patent proprietor in a eurasian patent |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |